Scrip’s Five Must-Know Things – 26 April 2021 by Citeline

In this week’s podcast, Medtech Insight managing editor Elizabeth Orr discussed the implications for medtech patent law from the US Supreme Court’ Minerva Surgical v. Hologic Inc. case. Ferdous Al-Faruque outlined the USPTO’s efforts to encourage inventors to file for COVID-19 product patents.

Scrip’s Five Must-Know Things – 20 April 2021 by Citeline

Pink Sheet reporters and editors discuss the response to the rare blood clots seen with Janssen’s COVID-19 vaccine, the US FDA’s new virtual facility inspection guidance, and the new permanent director of the Center for Drug Evaluation and Research.

In this week’s podcast, Medtech Insight's managing editor Marion Webb discusses plans by the Mayo Clinic and Veterans Health Administration to position themselves as medical device makers of 3D printing technologies. UK-based reporter Barnaby Pickering gives an overview of the global market for arthroscopy and sports medicine products.

Listen to the podcast via the player below:

https://medtech.pharmaintelligence.informa.com/MT143767/MDM-BIOMEDigital-2021-There-is-No-Easy-Button-On-3D-Printing-Panelist-Says

https://medtech.pharmaintelligence.informa.com/MT143752/Market-Brief-Global-Market-For-Arthroscopy-And-Sports-Medicine-Products-Will-Reach-63Bn-By-2025

https://medtech.pharmaintelligence.informa.com/MT143779/Reimbursement-Dispute-Between-Novitas-And-iRhythm-Hits-An-Impasse

For more information on Medtech Insight and to start a free trial, click here:

http://bit.ly/2w7LnlR

Medtech Insight articles addressing topics discussed in this episode:

HBW Insight editors discuss the latest European consumer healthcare industry news. This week, Tom Gallen and David Ridley look at some predictions for the future of the UK and European CBD market. Some experts see the market in two or three years dominated by big pharma, and with many products going the OTC medicines route, while others expect CBD firms in the UK to challenge the country's food regulator, the FSA, for what they call its "muddled" approach to bringing order to the already well-established British cannabidiol food supplements market.

Scrip’s Five Must-Know Things – 12 April 2021 by Citeline

In this week’s case study podcast we discuss first-of-their-kind US FDA emergency use authorizations for at-home COVID-19 diagnostics made by Lucira Health and Ellume.

Pink Sheet reporters and editor discuss the influence of the emergency use authorization on FDA decisions, another twist in the march-in rights debate, and how CBER is not using the real-time oncology review program.

The FDA’s outgoing second-in-command, Amy Abernethy, is confident she’s leaving the agency in good hands but plans to continue to advocate for patients by focusing on areas such as trial design and use of real-world evidence. In this interview with Medtech Insight, Abernethy also talks about the work she put in to make sure there was a change in IT culture at the agency, among other topics.